share_log

Livzon Pharmaceutical Group's (SZSE:000513) Shareholders May Want To Dig Deeper Than Statutory Profit

Livzon Pharmaceutical Group's (SZSE:000513) Shareholders May Want To Dig Deeper Than Statutory Profit

立華製藥集團(SZSE:000513)的股東可能希望深入挖掘不僅僅是法定利潤
Simply Wall St ·  2024/10/30 15:09

Livzon Pharmaceutical Group Inc.'s (SZSE:000513) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

立營藥業集團股份有限公司(SZSE:000513)最近強勁的盈利並沒有對股票產生太大影響。我們相信股東已經注意到一些超出法定利潤數字之外的擔憂因素。

big
SZSE:000513 Earnings and Revenue History October 30th 2024
SZSE:000513 每股收益和營業收入歷史數據 2024年10月30日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Livzon Pharmaceutical Group's profit received a boost of CN¥199m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

重要的是,我們的數據顯示,立營藥業集團的利潤在過去一年中因飛凡項目獲得了19900萬元人民幣的提振。雖然我們喜歡看到利潤增長,但當飛凡項目做出重大貢獻時,我們通常會更加謹慎。當我們分析了成千上萬家上市公司的數據後,我們發現,某一年中由飛凡項目帶來的提振往往不會在下一年重複出現。畢竟,這正是會計術語所暗示的。假設這些飛凡項目在當前年度不再出現,那麼我們預計明年的利潤會較弱(在沒有業務增長的情況下)。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Livzon Pharmaceutical Group's Profit Performance

我們對立營藥業集團的利潤表現看法

Arguably, Livzon Pharmaceutical Group's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Livzon Pharmaceutical Group's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 18% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. At Simply Wall St, we found 1 warning sign for Livzon Pharmaceutical Group and we think they deserve your attention.

可以說,立卓藥業集團的法定收益被飛凡項目扭曲,提振了利潤。因此,我們認爲立卓藥業集團的法定利潤可能比其潛在盈利能力更好。但至少持有者可以從過去三年每股收益每年增長18%中得到一些安慰。最終,如果您想正確了解該公司,則有必要考慮不僅僅是以上因素。因此,如果您想深入研究這支股票,關注它面臨的任何風險是至關重要的。在Simply Wall St,我們發現立卓藥業集團存在1個警告信號,我們認爲這是值得您注意的。

Today we've zoomed in on a single data point to better understand the nature of Livzon Pharmaceutical Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天,我們聚焦於一個數據點,以更好地了解立卓藥業集團利潤的性質。但還有許多其他方法可以幫助您形成對公司的看法。一些人認爲高股權回報率是優質企業的良好跡象。雖然這可能需要您做一些研究,但您可能會發現這個免費的公司收集股權回報率高的公司,或者這份具有重要內部持股的股票清單對您有所幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論